share_log

8-K: Poll Results of 2024 Stockholders Meeting

8-K: Poll Results of 2024 Stockholders Meeting

8-K：2024年股東大會會議決議公告
美股sec公告 ·  05/13 16:34
Moomoo AI 已提取核心訊息
Cassava Sciences, Inc., a biopharmaceutical company, held its 2024 Annual Meeting of Stockholders on May 9, 2024. The meeting was conducted virtually with a quorum of approximately 62% of the shares represented. During the meeting, three key proposals were voted upon. The first proposal involved the election of three nominees to the Board of Directors, with Remi Barbier, Sanford R. Robertson, and Patrick J. Scannon, M.D., Ph.D. being elected for a three-year term. The second proposal was the ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024, which passed with a significant majority. The third proposal, a non-binding advisory vote on the 2023 executive compensation for the named executive officers, was also approved. The results of the votes were detailed in the company's definitive proxy statement filed with the U.S. Securities and Exchange Commission on March 26, 2024.
Cassava Sciences, Inc., a biopharmaceutical company, held its 2024 Annual Meeting of Stockholders on May 9, 2024. The meeting was conducted virtually with a quorum of approximately 62% of the shares represented. During the meeting, three key proposals were voted upon. The first proposal involved the election of three nominees to the Board of Directors, with Remi Barbier, Sanford R. Robertson, and Patrick J. Scannon, M.D., Ph.D. being elected for a three-year term. The second proposal was the ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024, which passed with a significant majority. The third proposal, a non-binding advisory vote on the 2023 executive compensation for the named executive officers, was also approved. The results of the votes were detailed in the company's definitive proxy statement filed with the U.S. Securities and Exchange Commission on March 26, 2024.
生物製藥公司木薯科學公司於2024年5月9日舉行了2024年年度股東大會。會議以虛擬方式進行，法定人數約佔所代表股份的62％。會議期間，對三項關鍵提案進行了表決。第一項提案涉及選舉三名董事會候選人，當選的雷米·巴比爾、桑福德·羅伯遜和醫學博士帕特里克·斯坎農博士任期三年。第二項提案是批准安永會計師事務所作爲截至2024年12月31日的財政年度的獨立註冊會計師事務所，該提案以絕大多數獲得通過。第三項提案，即對指定執行官的2023年高管薪酬進行不具約束力的諮詢投票，也獲得批准。投票結果詳見該公司於2024年3月26日向美國證券交易委員會提交的最終委託書。
生物製藥公司木薯科學公司於2024年5月9日舉行了2024年年度股東大會。會議以虛擬方式進行，法定人數約佔所代表股份的62％。會議期間，對三項關鍵提案進行了表決。第一項提案涉及選舉三名董事會候選人，當選的雷米·巴比爾、桑福德·羅伯遜和醫學博士帕特里克·斯坎農博士任期三年。第二項提案是批准安永會計師事務所作爲截至2024年12月31日的財政年度的獨立註冊會計師事務所，該提案以絕大多數獲得通過。第三項提案，即對指定執行官的2023年高管薪酬進行不具約束力的諮詢投票，也獲得批准。投票結果詳見該公司於2024年3月26日向美國證券交易委員會提交的最終委託書。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息